When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets. | When it comes to GSK’s ...
In GSK’s first quarter with Luke Miels as CEO, the company’s flagship shingles vaccine Shingrix set a new quarterly sales ...
GSK has entered an exclusive strategic collaboration with Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing ...
SAN FRANCISCO—It was just about a year ago when GlaxoSmithKline sealed its deal for Tesaro, bringing on already-marketed PARP inhibitor Zejula. But don’t expect the company to spring for more ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Firms will share European profits in postmenopausal osteoporosis, while GSK gains control in emerging markets for all indications. GlaxoSmithKline (GSK) negotiated a $120 million deal to obtain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results